공고 • Jan 29
WntResearch AB to Report Fiscal Year 2024 Results on Feb 27, 2025 WntResearch AB announced that they will report fiscal year 2024 results on Feb 27, 2025 New Risk • Dec 11
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr50m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr50m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 9.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (116% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (kr5.39m market cap, or US$490.8k). 공고 • Oct 23
WntResearch AB to Report Q3, 2024 Results on Nov 21, 2024 WntResearch AB announced that they will report Q3, 2024 results on Nov 21, 2024 공고 • Oct 10
Wntresearch Provides an Update on the Work in Progress to Safeguard the Interests of Shareholders and Company Values WntResearch provides an update on the work to secure company values following the negative initial outcome analysis of the phase 2 study NeoFox. The company's drug candidate Foxy-5 showed no effect on tumors and lymph nodes as evaluated by CT, which therefore does not justify a continuation of the study. In order to safeguard the interests of the shareholders, the Board of Directors and management are working intensively on several parallel tracks where a goal is to complete a merger or a reverse acquisition. The Phase 2 clinical study NeoFox aimed to establish proof-of-concept for the drug candidate Foxy-5 for the treatment of colon cancer. The study included a total of 27 patients before it was stopped, including 16 patients on Foxy-5, and 11 patients in the control group, as previously announced. The initial result reading showed a favorable safety profile for Foxy-5, but without significant clinical benefit. The reason for the early analysis was to support the continued funding of the NeoFox study. However, no clinically relevant effects were seen on any of the study's crucial endpoints, which could be assessed in 15 out of 16 Foxy-5 patients, neither at half dose (n=3) nor at full dose (n=12). These endpoints were analyzed by CT scanning and included assessment of tumor size, as well as the number and size of lymph nodes, before and after treatment with Foxy-5. The exploratory endpoints included vascular and perineural invasion and were evaluated by tissue analysis of the surgically removed cancer tissue. In these analyses, the two groups are compared with each other. However, the number of patients who could be evaluated in each group was so limited (7 controls, 10 patients with full dose Foxy-5 and 3 patients with half dose Foxy-5) that it is impossible to draw any conclusiongs from the exploratory endpoints. To justify continued investments in the development of Foxy-5 for this indication, it would have been necessary to demonstrate large effects by CT already at this initial evaluation. The Company is of the view that the results achieved significantly reduce the possibility to raise additional money via future option programs or to attract a partner who would be willing to finance the extensive development program that wouldbe necessary for taking the drug canditade towards a future market approval. As a result, WntResearch decided to discontinue the study and has started to reduce the cost base and to safeguard the values that remain in the company. Discussions are ongoing with other companies regarding the possibility of carrying out a merger, reverse acquisition or similar. In parallel, the Board of Directors and management of WntResearch are also evaluating opportunities to realize the remaining value of the drug substance and the patent portfolio, and broadening the scope to pharmaceutical companies interested in the WNT signaling pathway both inside and outside oncology. New Risk • Sep 17
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr8.96m (US$880.0k) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Earnings have declined by 8.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (184% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (kr8.96m market cap, or US$880.0k). Minor Risk Less than 1 year of cash runway based on current free cash flow (-kr45m). New Risk • Aug 23
New minor risk - Financial position The company has less than a year of cash runway based on its current free cash flow. Free cash flow: -kr45m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 8.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (184% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr45m). Market cap is less than US$100m (kr123.8m market cap, or US$12.0m). 
